Commonwealth Diagnostics International, Inc.   Report issue

For profit Phase 4
Founded: Salem MA United States (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2019
NCT03729271
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Commonwealth Diagnostics International, Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

rifaximin (xifaxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diarrhea (Phase 4)

Irritable Bowel Syndrome (Phase 4)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 1